Paper
Eicosanoid biosynthesis and action: novel opportunities for pharmacological intervention
Published Jun 1, 1989 · S. Nicosia, C. Patrono
The FASEB Journal
44
Citations
0
Influential Citations
Abstract
Novel eicosanoid biosynthetic pathways and receptors are reviewed as potential targets for pharmacological intervention. In addition to the cyclooxygenase and lipoxygenase pathways of arachidonate metabolism, a cytochrome P450‐dependent monooxygenase has been identified in corneal and renal epithelial cells. Elucidation of the enzymatic pathways of thromboxane (TX) disposition and development of analytical techniques for measuring urinary metabolites have allowed a reliable assessment of TXA2 biosynthesis in health and disease, and provide a rationale for the combined use of TX‐synthase inhibitors and TXA2‐receptor antagonists in the setting of platelet activation. Recent evidence for a transcellular metabolism of neutrophilderived leukotriene (LT) A4 by other human blood cells might link platelet and neutrophil activation to the occurrence of vasospastic phenomena. Prostacyclin (PG12), PGE2, PGD2, TXA2/PGH2, and sulfidopeptide‐LT receptors are being characterized in terms of distribution, signal‐transduction mechanisms, and agonist‐mediated regulation. Development of relatively selective agonists and antagonists of these receptors is providing novel therapeutic strategies for several human diseases.—Nicosia, S.; Patrono, C. Eicosanoid biosynthesis and action: novel opportunities for pharmacological intervention. FASEB J. 3: 1941‐1948; 1989.
Novel eicosanoid biosynthetic pathways and receptors offer potential targets for pharmacological intervention, offering novel therapeutic strategies for various human diseases.
Full text analysis coming soon...